Clinical trial

Gemigliptin, Dapagliflozin, Empagliflozin DDI Study

NCT03565458

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2018-04-05

PhasePHASE1

Study timeline

Study start (actual)2018-04-05Date precision: day

Registry last updated2018-06-21

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Type 2 Diabetes Mellitusunresolved

Interventions

GemigliptinDRUG

DapagliflozinDRUG · verified · RxNorm: dapagliflozin

EmpagliflozinDRUG · verified · RxNorm: empagliflozin

Sponsors & collaborators

LG Chemlead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03565458 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.